Cas:20312-36-1 L-(-)-3-Phenyllactic acid manufacturer & supplier

Chemical Name:L-(-)-3-Phenyllactic acid

CAS.NO:20312-36-1

Synonyms:(2S)-2-Hydroxy-3-phenylpropanoic acid;(S)-2-Hydroxy-3-phenylpropionic acid;(S)-(-)-3-Phenyllactic Acid;EINECS 243-726-5;l-2-hydroxy-3-phenyl-propionic acid;Benzenepropanoic acid, α-hydroxy-, (S)-;L−(−)-3-Phenyllactic acid;L-3-Phenyllactic acid;2209792;D-3-phenyllactic acid;Benzenepropanoic acid, α-hydroxy-, (αS)-;L-(-)-Phenyllactic Acid;(S)-PhCH2CH(OH)CO2H;(S)-(-)-2-Hydroxy-3-phenylpropionic acid;L-(-)-3-Phenyllactic acid;(S)-2-Hydroxy-3-phenylpropanoic acid;MFCD00004244;(S)-(−)-3-Phenyllactic acid

Molecular Formula:C₉H₁₀O₃

Molecular Weight:166.174

HS Code:29181980

Physical and Chemical Properties:

Melting point:121-125ºC

Boiling point:331.6±22.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.577

PSA:57.53000

Exact Mass:166.062988

LogP:1.05

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like (2S)-2-Hydroxy-3-phenylpropanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(S)-(−)-3-Phenyllactic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(S)-2-Hydroxy-3-phenylpropanoic acid Use and application,L-(-)-3-Phenyllactic acid technical grade,usp/ep/jp grade.

Related News: What’s more, also at the EHA meeting, BeiGene’s Brukinsa showed it could outperform Imbruvica at triggering tumor responses while causing fewer cases of atrial fibrillation, a potentially dangerous heart side effect, in its own head-to-head phase 3 study in previously treated CLL. L-(-)-3-Phenyllactic acid manufacturer Among 30,000 volunteers — all of them from either the United States or Mexico — vaccinated people were completely protected against severe and even moderate cases of illness. L-(-)-3-Phenyllactic acid supplier The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. L-(-)-3-Phenyllactic acid vendor What’s more, also at the EHA meeting, BeiGene’s Brukinsa showed it could outperform Imbruvica at triggering tumor responses while causing fewer cases of atrial fibrillation, a potentially dangerous heart side effect, in its own head-to-head phase 3 study in previously treated CLL. L-(-)-3-Phenyllactic acid factory Among 30,000 volunteers — all of them from either the United States or Mexico — vaccinated people were completely protected against severe and even moderate cases of illness.